Immunoprecipitation (IP) is a common research technique used to precipitate a specific protein (or protein complex) of interest out of a heterogeneous lysate. The concept of precipitating proteins out of solution is often called a "pull-down". There are a variety of methods to achieve immunoprecipitation, the most common of which uses antibodies bound to magnetic or agarose beads. This process can be used to isolate and concentrate a particular protein or complex from a sample containing many thousands of different proteins, and is often used to study protein-protein interactions through Co-IP experiments.
Novus offers a range of support options for IP when you buy a product to help you with your IP experiment including:
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-77528SS | |||
| Azide and BSA Free | NBP2-80631 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-1832SS | |||
| Azide and BSA Free | NBP2-80962 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB936-SP | |||
| Carrier Free | MAB936-500 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF5869-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-314SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-80755 | |||
| BSA Free | NBP1-19015SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-58771SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB500-237SS | |||
| Azide and BSA Free | NBP2-80968 | |||
![Flow Cytometry: CD161/NK1.1 Antibody (PK136) [NB100-77528] - Analysis using the PE/Cy7 conjugate of NB100-77528. Staining of C57BL/6 splenocytes with Anti-Mouse CD49b (Integrin alpha 2) FITC and staining buffer (autofluorescence) (left) or Anti-Mouse NK1.1 PE-Cy7 (right). Total viable cells were used for analysis.](http://images.novusbio.com/fullsize/CD161-NK1-1-Antibody-PK136-Flow-Cytometry-NB100-77528-img0008.jpg "Flow Cytometry: CD161/NK1.1 Antibody (PK136) [NB100-77528] - Analysis using the PE/Cy7 conjugate of NB100-77528. Staining of C57BL/6 splenocytes with Anti-Mouse CD49b (Integrin alpha 2) FITC and staining buffer (autofluorescence) (left) or Anti-Mouse NK1.1 PE-Cy7 (right). Total viable cells were used for analysis.")
![Flow Cytometry: CD161/NK1.1 Antibody (PK136) [NB100-77528] - Mouse splenocytes were stained with CD49b (DX5) APC and purified NK1.1 (clone PK136) (top) or mouse IgG2a isotype control (bottom), followed by anti-mouse IgG2a FITC.](http://images.novusbio.com/fullsize/CD161-NK1-1-Antibody-PK136-Flow-Cytometry-NB100-77528-img0001.jpg)
![Flow Cytometry: CD161/NK1.1 Antibody (PK136) [NB100-77528] - C57BL/6 mouse splenocytes stained with purified PK136, followed by anti-mouse IgG2a FITC](http://images.novusbio.com/fullsize/CD161-NK1-1-Antibody-PK136-Flow-Cytometry-NB100-77528-img0002.jpg)
![Flow Cytometry: CD161/NK1.1 Antibody (PK136) [NB100-77528] - Mouse.](http://images.novusbio.com/fullsize/CD161-NK1-1-Antibody-PK136-Flow-Cytometry-NB100-77528-img0004.jpg)
![Flow Cytometry: CD161/NK1.1 Antibody (PK136) [NB100-77528] - Staining of C57BL/6 mouse splenocytes with Anti-Mouse NK-1.1 PE and Anti-Mouse CD49b (Integrin alpha 2) FITC. Total viable cells were used for analysis.](http://images.novusbio.com/fullsize/CD161-NK1-1-Antibody-PK136-Flow-Cytometry-NB100-77528-img0005.jpg)
![Flow Cytometry: CD161/NK1.1 Antibody (PK136) [NB100-77528] - Analysis using the PerCP/Cy5.5 conjugate of NB100-77528. Staining of C57BL/6 splenocytes with Anti-Mouse CD49b (Integrin alpha 2) APC and 0.25 ug of Mouse IgG2a K Isotype Control PerCP-Cy5.5 (left) or 0.25 ug of Anti-Mouse NK1.1 PerCP-Cy5.5 (right). Total viable cells were used for analysis.](http://images.novusbio.com/fullsize/CD161-NK1-1-Antibody-PK136-Flow-Cytometry-NB100-77528-img0009.jpg)
![Western Blot: ENO3 Antibody (5D1) [H00002027-M01] - Analysis of ENO3 expression in transfected 293T cell line by ENO3 monoclonal antibody (M01), clone 5D1.Lane 1: ENO3 transfected lysate(46.9 KDa).Lane 2: Non-transfected lysate.](http://images.novusbio.com/fullsize/ENO3-Antibody-5D1-Western-Blot-H00002027-M01-img0017.jpg "Western Blot: ENO3 Antibody (5D1) [H00002027-M01] - Analysis of ENO3 expression in transfected 293T cell line by ENO3 monoclonal antibody (M01), clone 5D1.Lane 1: ENO3 transfected lysate(46.9 KDa).Lane 2: Non-transfected lysate.")
![Immunocytochemistry/Immunofluorescence: ENO3 Antibody (5D1) [H00002027-M01] - Analysis of monoclonal antibody to ENO3 on HeLa cell. Antibody concentration 10 ug/ml.](http://images.novusbio.com/fullsize/ENO3-Antibody-5D1-Immunocytochemistry-Immunofluorescence-H00002027-M01-img0009.jpg)
![Immunohistochemistry-Paraffin: ENO3 Antibody (5D1) [H00002027-M01] - Analysis of monoclonal antibody to ENO3 on formalin-fixed paraffin-embedded human colon. Antibody concentration 3 ug/ml.](http://images.novusbio.com/fullsize/ENO3-Antibody-5D1-Immunohistochemistry-Paraffin-H00002027-M01-img0013.jpg)
![Western Blot: ENO3 Antibody (5D1) [H00002027-M01] - Analysis of ENO3 over-expressed 293 cell line, cotransfected with ENO3 Validated Chimera RNAi ( Cat # H00002027-R01V ) (Lane 2) or non-transfected control (Lane 1). Blot probed with ENO3 monoclonal antibody (M01), clone 5D1 (Cat # H00002027-M01 ). GAPDH ( 36.1 kDa ) used as specificity and loading control.](http://images.novusbio.com/fullsize/ENO3-Antibody-5D1-Western-Blot-H00002027-M01-img0014.jpg)
![Western Blot: ENO3 Antibody (5D1) [H00002027-M01] - ENO3 monoclonal antibody (M01), clone 5D1 Analysis of ENO3 expression in HeLa.](http://images.novusbio.com/fullsize/ENO3-Antibody-5D1-Western-Blot-H00002027-M01-img0016.jpg)
![Immunohistochemistry-Paraffin: ENO3 Antibody (5D1) [H00002027-M01] - Analysis of monoclonal antibody to ENO3 on formalin-fixed paraffin-embedded human stomach. Antibody concentration 1.5 ug/ml.](http://images.novusbio.com/fullsize/ENO3-Antibody-5D1-Immunohistochemistry-Paraffin-H00002027-M01-img0011.jpg)
![ELISA: ENO3 Antibody (5D1) [H00002027-M01] - Detection limit for recombinant GST tagged ENO3 is approximately 0.03ng/ml as a capture antibody.](http://images.novusbio.com/fullsize/ENO3-Antibody-5D1-ELISA-H00002027-M01-img0018.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. Protein expression of Foxo1, Foxo3, and phospho-T24/32 Foxo1/3 in young (<3-month, n = 6), adult (3-18-month, n = 6), and old (18-20-month, n = 6) FVB/B6 mixed-strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean +/- SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t-test. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1111/acel.12701), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Western-Blot-NB100-614-img0014.jpg "Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. Protein expression of Foxo1, Foxo3, and phospho-T24/32 Foxo1/3 in young (<3-month, n = 6), adult (3-18-month, n = 6), and old (18-20-month, n = 6) FVB/B6 mixed-strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean +/- SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t-test. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1111/acel.12701), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: FOXO3 Antibody [NB100-614] - Analysis of FOXO3 in human B cell lymphoma using anti-FOXO3 antibody .Image submitted by a verified customer review.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunocytochemistry-Immunofluorescence-NB100-614-img0007.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NB100-614] - Sample: FFPE section of human ovarian carcinoma (left) and mouse renal cell carcinoma (right). Antibody: Affinity purified rabbit anti-FOXO3a used at a dilution of 1:1,000 (1ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-NB100-614-img0009.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: FOXO3 Antibody [NB100-614] - Detection of Human and Mouse FOXO3a by Western Blot. Samples: Whole cell lysate (50 ug) from HeLa, 293T, Jurkat, mouse TCMK-1, and mouse NIH3T3 cells. Antibodies: Affinity purified rabbit anti-FOXO3a antibody NB100-614 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Western-Blot-NB100-614-img0011.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - FOXO3 Protein expression levels both control group and exercise group for skeletal muscles. Image submitted by a verified customer review *{Mouse WB}*](http://images.novusbio.com/fullsize/FOXO3-Antibody-Western-Blot-NB100-614-img0012.jpg)
![<b>Independent Antibodies Validation. </b>Immunoprecipitation: FOXO3 Antibody [NB100-614] - Detection of human FOXO3a by western blot of immunoprecipitates. Samples: Whole cell lysate (1 mg for IP; 20% of IP loaded) from MCF-7 cells. Antibodies: Affinity purified rabbit anti-FOXO3a antibody NB100-614 used for IP at 6 ug/mg lysate. FOXO3a was also immunoprecipitated by rabbit anti-FOXO3a antibody NB100-613. For blotting immunoprecipitated FOXO3a, NB100-614 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunoprecipitation-NB100-614-img0013.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. Representative Western blotting results. Foxo1- or Foxo1/3-specific knockouts (1KO or 1/3KO) selectively lost targeted isoforms. CBM-cerebellum, STR-striatum, SCD-spinal cord, CTX-cortex, BST-brain stem, MDB-midbrain, HPC-hippocampus.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Knockout-Validated-NB100-614-img0015.jpg)
![Western Blot: Rabbit Polyclonal FOXO3 Antibody [NB100-614] - Analysis of FOXO3 and FOXM1in parental HCT-116 and HCT-116-FUR cells. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-614_rabbit-polyclonal-foxo3-antibody-western-blot-1652024104015.png)
![Western Blot: FOXO3 Antibody [NB100-614] - Increased proteotoxic stress & defective autophagy in Foxo1/3/4 knockout mice. (a) Tissue lysates from 12‐month‐old WT & KO brain cortex were analyzed by WB of indicated proteins. (c) p62 IF & (d) p62 & Ub IHC on cortical neurons from 12‐month‐old WT & KO brain cortex. Red arrows point to labeling positive inclusions. Scale bar = 200 μm. (e) Quantitation of representative results for (d). (f) Indicated genotype of neural progenitor cultures was differentiated into neurons for 5 days. Some cultures were treated with rapamycin (100 ng/ml) for 24 hr on day 4 of differentiation. (h) The autophagy activity was analyzed by flow cytometry. The bar graph shows autophagy indices as % of control of (f). (i) Cultures as in (f) were treated with chloroquine (100 ng/ml) for 4 hr & analyzed for the expression levels of LC3 by WB. Representative result from three to five independent experiments is shown. (b, g, j) Quantitation of WB band densities. Only chloroquine‐treated cultures were statistically compared in (j). Error bars, mean ± SEM. *p < .05. **p < .01, ***p < .005; ****p < .001. Statistical significance was determined by one‐way ANOVA Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-614_rabbit-polyclonal-foxo3-antibody-310202415541916.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. (a) XY plots of FOXO1 or FOXO3 mRNA expression within the noted brain regions vs. age of the subjects at time of death. (b) Pearson correlation coefficients (r) & p‐values for the correlation of FOXO1 or FOXO3 mRNA expression in various regions of the human brain with the age. (c) The mRNA expressions of FOXO1 & FOXO3 were measured in human cerebellums (n = 33). Blue & green dots indicate samples used for WB in (d). The mRNA (e) & protein (f) expression of Foxo1, Foxo3, & phospho‐T24/32 Foxo1/3 in young (<3‐month, n = 6), adult (3‐18‐month, n = 6), & old (18–20‐month, n = 6) FVB/B6 mixed‐strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean ± SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t‐test. (g) FOXO1 IHC analysis of brain sections of WT & Foxo 1/3/4 KO mice. Residual FOXO1 immunoreactivity in KO mice is visible in endothelial cells (inset). Scale bar = 200 μm. (h) RT‐qPCR results for Foxo1 & Foxo3 mRNA. Empty bars represent WT, & colored bars represent KO tissues (n = 4). (i) Representative Western blotting results. Foxo1‐ or Foxo1/3‐specific knockouts (1KO or 1/3KO) selectively lost targeted isoforms. CBM—cerebellum, STR—striatum, SCD—spinal cord, CTX—cortex, BST—brain stem, MDB—midbrain, HPC—hippocampus Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-614_rabbit-polyclonal-foxo3-antibody-310202415535143.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. (a) XY plots of FOXO1 or FOXO3 mRNA expression within the noted brain regions vs. age of the subjects at time of death. (b) Pearson correlation coefficients (r) & p‐values for the correlation of FOXO1 or FOXO3 mRNA expression in various regions of the human brain with the age. (c) The mRNA expressions of FOXO1 & FOXO3 were measured in human cerebellums (n = 33). Blue & green dots indicate samples used for WB in (d). The mRNA (e) & protein (f) expression of Foxo1, Foxo3, & phospho‐T24/32 Foxo1/3 in young (<3‐month, n = 6), adult (3‐18‐month, n = 6), & old (18–20‐month, n = 6) FVB/B6 mixed‐strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean ± SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t‐test. (g) FOXO1 IHC analysis of brain sections of WT & Foxo 1/3/4 KO mice. Residual FOXO1 immunoreactivity in KO mice is visible in endothelial cells (inset). Scale bar = 200 μm. (h) RT‐qPCR results for Foxo1 & Foxo3 mRNA. Empty bars represent WT, & colored bars represent KO tissues (n = 4). (i) Representative Western blotting results. Foxo1‐ or Foxo1/3‐specific knockouts (1KO or 1/3KO) selectively lost targeted isoforms. CBM—cerebellum, STR—striatum, SCD—spinal cord, CTX—cortex, BST—brain stem, MDB—midbrain, HPC—hippocampus Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-614_rabbit-polyclonal-foxo3-antibody-3102024155456.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - Increased proteotoxic stress & defective autophagy in Foxo1/3/4 knockout mice. (a) Tissue lysates from 12‐month‐old WT & KO brain cortex were analyzed by WB of indicated proteins. (c) p62 IF & (d) p62 & Ub IHC on cortical neurons from 12‐month‐old WT & KO brain cortex. Red arrows point to labeling positive inclusions. Scale bar = 200 μm. (e) Quantitation of representative results for (d). (f) Indicated genotype of neural progenitor cultures was differentiated into neurons for 5 days. Some cultures were treated with rapamycin (100 ng/ml) for 24 hr on day 4 of differentiation. (h) The autophagy activity was analyzed by flow cytometry. The bar graph shows autophagy indices as % of control of (f). (i) Cultures as in (f) were treated with chloroquine (100 ng/ml) for 4 hr & analyzed for the expression levels of LC3 by WB. Representative result from three to five independent experiments is shown. (b, g, j) Quantitation of WB band densities. Only chloroquine‐treated cultures were statistically compared in (j). Error bars, mean ± SEM. *p < .05. **p < .01, ***p < .005; ****p < .001. Statistical significance was determined by one‐way ANOVA Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-614_rabbit-polyclonal-foxo3-antibody-3102024155375.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. (a) XY plots of FOXO1 or FOXO3 mRNA expression within the noted brain regions vs. age of the subjects at time of death. (b) Pearson correlation coefficients (r) & p‐values for the correlation of FOXO1 or FOXO3 mRNA expression in various regions of the human brain with the age. (c) The mRNA expressions of FOXO1 & FOXO3 were measured in human cerebellums (n = 33). Blue & green dots indicate samples used for WB in (d). The mRNA (e) & protein (f) expression of Foxo1, Foxo3, & phospho‐T24/32 Foxo1/3 in young (<3‐month, n = 6), adult (3‐18‐month, n = 6), & old (18–20‐month, n = 6) FVB/B6 mixed‐strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean ± SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t‐test. (g) FOXO1 IHC analysis of brain sections of WT & Foxo 1/3/4 KO mice. Residual FOXO1 immunoreactivity in KO mice is visible in endothelial cells (inset). Scale bar = 200 μm. (h) RT‐qPCR results for Foxo1 & Foxo3 mRNA. Empty bars represent WT, & colored bars represent KO tissues (n = 4). (i) Representative Western blotting results. Foxo1‐ or Foxo1/3‐specific knockouts (1KO or 1/3KO) selectively lost targeted isoforms. CBM—cerebellum, STR—striatum, SCD—spinal cord, CTX—cortex, BST—brain stem, MDB—midbrain, HPC—hippocampus Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-614_rabbit-polyclonal-foxo3-antibody-310202415525289.jpg)
![Western Blot: gp96/HSP90B1/GRP94 Antibody (9G10) [NB300-619] - Analysis of 25 ug of Hela (lane 1), C6 (lane 2) and NIH-3T3 (lane 3) lysates.](http://images.novusbio.com/fullsize/gp96-HSP90B1-GRP94-Antibody-9G10-Western-Blot-NB300-619-img0029.jpg "Western Blot: gp96/HSP90B1/GRP94 Antibody (9G10) [NB300-619] - Analysis of 25 ug of Hela (lane 1), C6 (lane 2) and NIH-3T3 (lane 3) lysates.")
![Immunocytochemistry/Immunofluorescence: gp96/HSP90B1/GRP94 Antibody (9G10) [NB300-619] - GR94 in human primary fibroblasts, ER staining. Primary antibody incubation: 1:250 in 10% Serum in PBST (0.1% Triton) O/N 4C. Secondary: Donkey anti-rat 647 1:500 2h RT. ICC/IF image submitted by a verifed customer review.](http://images.novusbio.com/fullsize/gp96-HSP90B1-GRP94-Antibody-9G10-Immunocytochemistry-Immunofluorescence-NB300-619-img0032.jpg)
![Immunohistochemistry-Paraffin: gp96/HSP90B1/GRP94 Antibody (9G10) [NB300-619] - Normal biopsies of deparaffinized Mouse breast tissue.](http://images.novusbio.com/fullsize/gp96-HSP90B1-GRP94-Antibody-9G10-Immunohistochemistry-Paraffin-NB300-619-img0028.jpg)
![Western Blot: gp96/HSP90B1/GRP94 Antibody (9G10) [NB300-619] - Analysis of 2-fold serial dilutions of HeLa cell lysate, starting at 10 ug, per well.](http://images.novusbio.com/fullsize/gp96-HSP90B1-GRP94-Antibody-9G10-Western-Blot-NB300-619-img0030.jpg)
![Immunocytochemistry/Immunofluorescence: gp96/HSP90B1/GRP94 Antibody (9G10) [NB300-619] - Analysis of Glucose-Regulated Protein 94 using Glucose-Regulated Protein 94 Monoclonal Antibody (9G10) shows staining in C6 Cells. Glucose-Regulated Protein 94 (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with an antibody recognizing Glucose-Regulated Protein 94 at a dilution of 1:100 over night at 4C, washed with PBS and incubated with a DyLight-488 conjugated.](http://images.novusbio.com/fullsize/gp96-HSP90B1-GRP94-Antibody-9G10-Immunocytochemistry-Immunofluorescence-NB300-619-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: gp96/HSP90B1/GRP94 Antibody (9G10) [NB300-619] - Analysis of Glucose-Regulated Protein 94 using Glucose-Regulated Protein 94 Monoclonal Antibody (9G10) shows staining in Hela Cells. Glucose-Regulated Protein 94 (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with an antibody recognizing Glucose-Regulated Protein 94 at a dilution of 1:100 over night at 4C, washed with PBS and incubated with a DyLight-488 conjugated.](http://images.novusbio.com/fullsize/gp96-HSP90B1-GRP94-Antibody-9G10-Immunocytochemistry-Immunofluorescence-NB300-619-img0018.jpg)
![Immunocytochemistry/Immunofluorescence: gp96/HSP90B1/GRP94 Antibody (9G10) [NB300-619] - Analysis of Glucose-Regulated Protein 94 using Glucose-Regulated Protein 94 Monoclonal Antibody (9G10) shows staining in NIH-3T3 Cells. Glucose-Regulated Protein 94 (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with an antibody recognizing Glucose-Regulated Protein 94 at a dilution of 1:20 over night at 4C, washed with PBS and incubated with a DyLight-488 conjugated.](http://images.novusbio.com/fullsize/gp96-HSP90B1-GRP94-Antibody-9G10-Immunocytochemistry-Immunofluorescence-NB300-619-img0019.jpg)
![Immunohistochemistry-Paraffin: gp96/HSP90B1/GRP94 Antibody (9G10) [NB300-619] - Normal biopsies of deparaffinized Mouse liver tissue.](http://images.novusbio.com/fullsize/gp96-HSP90B1-GRP94-Antibody-9G10-Immunohistochemistry-Paraffin-NB300-619-img0021.jpg)
![Immunohistochemistry-Paraffin: gp96/HSP90B1/GRP94 Antibody (9G10) [NB300-619] - Normal biopsies of deparaffinized Mouse lymph node.](http://images.novusbio.com/fullsize/gp96-HSP90B1-GRP94-Antibody-9G10-Immunohistochemistry-Paraffin-NB300-619-img0023.jpg)
![Immunohistochemistry-Paraffin: gp96/HSP90B1/GRP94 Antibody (9G10) [NB300-619] - Analysis of Glucose-Regulated Protein 94 (Grp94) in U2OS cells. Cells fixed with 4% paraformaldehyde were permeabilized with 0.1% Triton X-100 in PBS for 15 minutes at room temperature and blocked with 2% BSA in PBST (from Product # 37525) for 30 minutes at room temperature. Cells were treated with Peroxidase Suppressor, probed with a Grp94 monoclonal antibody at a dilution of 1:100 for at least 1 hour at room temperature, washed with PBST, and incubated with an HRP-conjugated goat anti-rat IgG (H+L) secondary antibody at a dilution of 1:1000 for 30 minutes at room temperature. Chromogenic detection was performed using Metal Enhanced DAB Substrate Kit.](http://images.novusbio.com/fullsize/gp96-HSP90B1-GRP94-Antibody-9G10-Immunohistochemistry-Paraffin-NB300-619-img0026.jpg)
![Immunohistochemistry-Paraffin: gp96/HSP90B1/GRP94 Antibody (9G10) [NB300-619] - Staining on poorly differentiated adenocarcinoma from paraffin-embedded human colon tissue sections.](http://images.novusbio.com/fullsize/gp96-HSP90B1-GRP94-Antibody-9G10-Immunohistochemistry-Paraffin-NB300-619-img0027.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Staining of human peripheral blood lymphocytes with anti-human CD45 antibody (MEM-28) Alexa Fluor 700.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0021.jpg "Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Staining of human peripheral blood lymphocytes with anti-human CD45 antibody (MEM-28) Alexa Fluor 700.")
![Immunocytochemistry/Immunofluorescence: CD45 Antibody (MEM-28) [NB500-319] - staining of human peripheral blood mononuclear cell using anti-human CD45 antibody (MEM-28) (green). DNA visualized by DAPI (blue).](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Immunocytochemistry-NB500-319-img0001.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) PE-CyTM5.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0018.jpg)
![Immunohistochemistry-Paraffin: CD45 Antibody (MEM-28) [NB500-319] - Staining of human small intestine (paraffin-embedded sections) with CD45 antibody (MEM-28), 10 ug/ml.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Immunohistochemistry-Paraffin-NB500-319-img0022.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Surface staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) PerCP-CyTM5.5.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0007.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Surface staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) purified, GAM-APC.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0008.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Surface staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) APC-CyTM7.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0010.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) Pacific BlueTM.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0016.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) PE.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0017.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) PE-CyTM7.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0019.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) PE-DyLight (R) 594.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0020.jpg)
![Immunocytochemistry/Immunofluorescence: SSEA-3 Antibody (MC-631) [NB100-1832] - PSC characterisation. Human PSC-1 characterized for typical undifferentiated colony morphology in expression of pluripotency markers Nanog (Catalog # AF1997), OCT-3/4 (Catalog # AF1759), SSEA-3 (NB100-1832), SSEA-4 (Catalog # MAB1435) after immunofluorescence staining. Corresponding nuclei stains with DAPI shown. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-33899-6), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SSEA-3-Antibody-MC-631-Immunocytochemistry-Immunofluorescence-NB100-1832-img0016.jpg "Immunocytochemistry/Immunofluorescence: SSEA-3 Antibody (MC-631) [NB100-1832] - PSC characterisation. Human PSC-1 characterized for typical undifferentiated colony morphology in expression of pluripotency markers Nanog (Catalog # AF1997), OCT-3/4 (Catalog # AF1759), SSEA-3 (NB100-1832), SSEA-4 (Catalog # MAB1435) after immunofluorescence staining. Corresponding nuclei stains with DAPI shown. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-33899-6), licensed under a CC-BY license.")
![Flow Cytometry: SSEA-3 Antibody (MC-631) [NB100-1832] - A surface stain was performed on Jurkat cells with SSEA-3 Antibody (MC-631) NB100-1832AF647 (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 5 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/SSEA-3-Antibody-MC-631-Flow-Cytometry-NB100-1832-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: SSEA-3 Antibody (MC-631) [NB100-1832] - Analysis of human embryonic stem cells stained with SSEA-3 antibody detected with Alexa Fluor 488 anti-rat IgM secondary antibody.](http://images.novusbio.com/fullsize/SSEA-3-Antibody-MC-631-Immunocytochemistry-Immunofluorescence-NB100-1832-img0012.jpg)
![Western Blot: hnRNP M1-M4 Antibody (1D8) [NB200-314] - Analysis of hnRNP M1-M4 in HeLa cell lysates using NB200-314.](http://images.novusbio.com/fullsize/hnRNP-M1-M4-Antibody-1D8-Western-Blot-NB200-314-img0004.jpg "Western Blot: hnRNP M1-M4 Antibody (1D8) [NB200-314] - Analysis of hnRNP M1-M4 in HeLa cell lysates using NB200-314.")
![Immunohistochemistry-Paraffin: hnRNP M1-M4 Antibody (1D8) [NB200-314] - Analysis of formalin fixed paraffin-embedded (FFPE) human tonsil using hnRNP M1-M4 (1D8) antibody at 1:500 on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes with DAB was used for signal development followed by counterstaining with hematoxylin. Nuclear riboprotein staining was observed.](http://images.novusbio.com/fullsize/hnRNP-M1-M4-Antibody-1D8-Immunohistochemistry-Paraffin-NB200-314-img0005.jpg)
![Western Blot: Glyoxalase I Antibody (Glo1a) [NBP1-19015] - Detection of GLO-1 in human cell lines. Lane 1,2 and 3: MG-63 osteosarcoma cell line (positive control), 402-91 liposarcoma cell line and 402-91 liposarcoma cell line resistant to trabectedine. Image from verified customer review.](http://images.novusbio.com/fullsize/Glyoxalase-I-Antibody-Glo1a-Western-Blot-NBP1-19015-img0007.jpg "Western Blot: Glyoxalase I Antibody (Glo1a) [NBP1-19015] - Detection of GLO-1 in human cell lines. Lane 1,2 and 3: MG-63 osteosarcoma cell line (positive control), 402-91 liposarcoma cell line and 402-91 liposarcoma cell line resistant to trabectedine. Image from verified customer review.")
![Immunocytochemistry/Immunofluorescence: Glyoxalase I Antibody (Glo1a) [NBP1-19015] - Immunostaining of human retinal endothelial cells. Immunoreactivity for hGlx-1 was detected in human retinal endothelial cells stained with Glo1a mAb using anti mouse IgG Texas Red as secondary Ab. The cells were counter stained with phalloidin (green) and DAPI (blue), nuclear stain. No reactivity was detected in control cells, stained without Go1a mAb. Figure is a representative of 3 independent experiments. Photo courtesy of Dr. Nagaraj, Case Western Reserve University.](http://images.novusbio.com/fullsize/Glyoxalase-I-Antibody-Glo1a-Immunocytochemistry-Immunofluorescence-NBP1-19015-img0004.jpg)
![Western Blot: Glyoxalase I Antibody (Glo1a) [NBP1-19015] - HeLa whole cell extracts.](http://images.novusbio.com/fullsize/Glyoxalase-I-Antibody-Glo1a-Western-Blot-NBP1-19015-img0003.jpg)
![Simple Western: Glyoxalase I Antibody (Glo1a) [NBP1-19015] - Simple Western lane view shows a specific band for GLO1 in 0.5 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230kDa separation system. * Non-specific interaction with the 230 kDa Simple Western standard may be seen with this antibody.](http://images.novusbio.com/fullsize/Glyoxalase-I-Antibody-Glo1a-Simple-Western-NBP1-19015-img0006.jpg)
![Simple Western: Glyoxalase I Antibody (Glo1a) [NBP1-19015] - Simple Western lane view shows a specific band detected for GLO1 in HeLa lysate. This experiment was performed under reducing conditions using the Wes or Sally Sue separation system 12-230kDa (or 66-440kDa).](http://images.novusbio.com/fullsize/Glyoxalase-I-Antibody-Glo1a-Simple-Western-NBP1-19015-img0005.jpg)
![Western Blot: LRRK2 Antibody [NB110-58771] - Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and LRRK2 knockout (KO) HeLa cell line. PVDF membrane was probed with 1:1000 of Rabbit Anti-Human LRRK2 Polyclonal Antibody (Catalog # NB110-58771) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog #HAF008). Specific band was detected for LRRK2 at approximately 275 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Knockout-Validated-NB110-58771-img0009.jpg "<b>Genetic Strategies Validation. </b>Western Blot: LRRK2 Antibody [NB110-58771] - Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and LRRK2 knockout (KO) HeLa cell line. PVDF membrane was probed with 1:1000 of Rabbit Anti-Human LRRK2 Polyclonal Antibody (Catalog # NB110-58771) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog #HAF008). Specific band was detected for LRRK2 at approximately 275 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.")
![<b>Genetic Strategies Validation. </b>Western Blot: LRRK2 Antibody [NB110-58771] - NB110-58771 in increasing amounts of human lymphoblast](http://images.novusbio.com/fullsize/LRRK2-Antibody-Western-Blot-NB110-58771-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: LRRK2 Antibody [NB110-58771] - Immunofluorescence of Lrrk2 with NB110-58771 within (A) Substantia nigra neurons (B) Chains of migrating neuroblasts.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunocytochemistry-Immunofluorescence-NB110-58771-img0008.jpg)
![Immunohistochemistry-Frozen: LRRK2 Antibody [NB110-58771] - DAB Immunostaining in frozen sections of mouse brainstem.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunohistochemistry-NB110-58771-img0006.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: LRRK2 Antibody [NB110-58771] - LRRK2 RNA levels 5 days after shRNA lentiviral transduction. The empty vector was used as the mock control. Lines represent the mean +/- SEM of three to four independent silencing experiments. A representative immunoblot analysis of LRRK2 protein levels 5 days after transduction is also shown. Beta-III-tubulin was the loading control. Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-016-0761-x) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Knockdown-Validated-NB110-58771-img0010.jpg)
![Western Blot: LRRK2 Antibody [NB110-58771] - Characterization of iPSC-derived DA neurons with LRRK2 mutations. a Diagram showing the DA differentiation protocol used for neural induction of human iPSC lines. b Temporal gene expression analyzed by qRT-PCR at three time points: induction (3 weeks), expansion (4–5 weeks), & maturation (>6 weeks). Each point represents the mean ± SEM of at least two independent differentiation experiments. c Representative images of mature neuronal cultures showing expression of neuronal ( beta III-tubulin, Tau, & alpha -synuclein) & dopaminergic (TH, NURR1) markers. Nuclei were counterstained with Hoechst. Scale bars: 50 μm. d Quantification of immunostainings. Data are represented as mean ± SEM of counts from at least two different lines for each genotype. e Representative western blot analyses of TH, Tau, & GFAP with beta III-tubulin as loading control in iPSC-derived mature neurons. f Representative immunoblots & quantification of LRRK2 expression in mature neuronal cultures. alpha -tubulin was the loading control & data were normalized to control WT neurons. Bars represent the mean ± SEM of at least two different lines per genotype. DIV days in vitro, GEL gelatin, POL poly-ornithine, FBN fibronectin, LMN laminin, N2 N2 supplement, bFGF basic fibroblast growth factor, SAG smoothened agonist, LDN LDN-193189, CHIR CHIR99021, SB SB431542, BDNF brain-derived neurotrophic factor, AA ascorbic acid, B27 B27 supplement, dbcAMP dibutyryl cyclic adenosine monophosphate, TGF beta III transforming growth factor beta III, GDNF glial derived neurotrophic factor. See Additional file 2 for uncropped blots Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-016-0761-x), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-58771_rabbit-polyclonal-lrrk2-antibody-31020241623559.jpg)
![Immunohistochemistry-Paraffin: Survivin Antibody (32.1) [NB500-237] - Survivin expression in human chondrosarcoma. Immunohistochemistry and immunoblot for survivin (red staining) from human chondrosarcoma specimens. Specimen of a grade III chondrosarcoma stained with monoclonal antibody, shows a similar pattern of staining. Image collected and cropped by Citeab from the following publication (The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro. BMC Cancer (2011) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Survivin-Antibody-32-1-Immunohistochemistry-Paraffin-NB500-237-img0004.jpg "Immunohistochemistry-Paraffin: Survivin Antibody (32.1) [NB500-237] - Survivin expression in human chondrosarcoma. Immunohistochemistry and immunoblot for survivin (red staining) from human chondrosarcoma specimens. Specimen of a grade III chondrosarcoma stained with monoclonal antibody, shows a similar pattern of staining. Image collected and cropped by Citeab from the following publication (The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro. BMC Cancer (2011) licensed under a CC-BY license.")
![Flow Cytometry: Survivin Antibody (32.1) [NB500-237] - An intracellular stain was performed on HeLa cells with FITC-conjugated Survivin Antibody (32.1) [NB500-237F] (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to FITC.](http://images.novusbio.com/fullsize/Survivin-Antibody-32-1-Flow-Cytometry-NB500-237-img0003.jpg)
![Immunohistochemistry-Paraffin: Survivin Antibody (32.1) [NB500-237] - Immunohistochemical staining of formalin-fixed paraffin-embedded human lung cancer tissue using Survivin Antibody (32.1) [NB500-237].](http://images.novusbio.com/fullsize/Survivin-Antibody-32-1-Immunohistochemistry-Paraffin-NB500-237-img0002.jpg)
![Western Blot: Survivin Antibody (32.1) - BSA Free [NB500-237] - Survivin expression in human chondrosarcoma. Immunohistochemistry & immunoblot for survivin (red staining) from human chondrosarcoma specimens. A: Low-power image of human high-grade chondrosarcoma displays strong cellular expression of survivin protein. B: High-power magnification reveals the predominantly cytoplasmic staining, although strong nuclear signals are detectable. C & D: Other specimen of a grade III chondrosarcoma stained with monoclonal antibody, shows a similar pattern of staining. E: Strong survivin signal in a tumor cell displaying a mitotic figure (arrow). F: To verify the expression of survivin in human chondrosarcoma, immunoblots were performed from 3 high grade chondrosarcoma lysates (Patient Nr. 5, 7, 10). As control for the correct molecular weight, in vitro-transcribed & -translated (IVTT) recombinant survivin protein, derived from the full-length human cDNA was loaded. Furthermore, lysates from adult human cartilage served as a negative control. Total protein loaded was 1 μg for recombinant human survivin, 60 μg for chondrosarcoma & cartilage lysates. For A, B & E the polyclonal rabbit anti-survivin antibody AF886 was used. For C & D the monoclonal mouse anti-survivin antibody clone 32.1 was used. Original magnifications: 200× (A & C) & 400× (B & D) & 600× (E). Image collected & cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-120), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-237_mouse-monoclonal-survivin-antibody-32-1-31020241616086.jpg)
